Maxim Group analyst Jason McCarthy maintained a Hold rating on Teva Pharma (TEVA) today. The company’s shares opened today at $17.18.
McCarthy commented:
“4Q18 revenues were mostly inline with estimates ($4.56B vs. $4.53B consensus), as was the bottom line with non-GAAP EPS of $0.53 vs. $0.55. However, guidance for 2019 was below expectations and as per management, 2019 will be the trough for Teva’s business. Teva ended the period with $1.8B in cash and $28.9B in debt. Nonetheless the company is making progress, in our view, with its restructuring program but it will take more time. Shares are off (~8%) following the earnings call this morning.”
According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.0% and a 33.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Aridis Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.
Currently, the analyst consensus on Teva Pharma is a Hold with an average price target of $21.68, representing a 26.2% upside. In a report issued on February 5, Credit Suisse also maintained a Hold rating on the stock with a $26 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.96 and a one-year low of $14.59. Currently, Teva Pharma has an average volume of 10.54M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines.
Read More on TEVA:
